FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene Editing ...
Arbor Biotechnologies™ received FDA clearance for ABO-101's IND application, targeting PH1 with a CRISPR-based therapy. The redePHine study will evaluate ABO-101's safety and efficacy in PH1 patients. ABO-101 aims to reduce oxalate levels by editing the HAO1 gene, offering a potential first-in-class treatment for PH1.
Reference News
FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene Editing ...
Arbor Biotechnologies™ received FDA clearance for ABO-101's IND application, targeting PH1 with a CRISPR-based therapy. The redePHine study will evaluate ABO-101's safety and efficacy in PH1 patients. ABO-101 aims to reduce oxalate levels by editing the HAO1 gene, offering a potential first-in-class treatment for PH1.